Comparative Pharmacology
Head-to-head clinical analysis: DEXEDRINE versus DYANAVEL XR 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXEDRINE versus DYANAVEL XR 10.
DEXEDRINE vs DYANAVEL XR 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
Category C
Category C
CNS Stimulant
CNS Stimulant